Heron Therapeutics Inc (HRTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Heron Therapeutics Inc (HRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9827
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses its proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company’s first commercial product,Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due tomoderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Heron’s developmental pipeline includes HTX-011 for post-operative pain management and Cinvanti (HTX-019) for chemotherapy-induced nausea and vomiting (CINV) prevention. Heron is headquartered in San Diego, California, the US.

Heron Therapeutics Inc (HRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heron Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Heron Therapeutics Raises USD200 Million in Public Offering of Shares 12
Heron Therapeutics Prices Public Offering of Shares for USD156 Million 14
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 16
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 17
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 19
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 21
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 23
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 24
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 26
Heron Therapeutics Inc – Key Competitors 27
Heron Therapeutics Inc – Key Employees 28
Heron Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Sep 30, 2018: Heron Therapeutics announces financial results for the three and nine months ended September 30, 2018 and recent corporate progress 30
Aug 08, 2018: Heron Therapeutics announces financial results for the three and six months ended june 30, 2018 and recent corporate progress 31
May 10, 2018: Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress 32
Feb 27, 2018: Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress 34
Nov 06, 2017: Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 36
Aug 09, 2017: Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 37
May 10, 2017: Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 38
Feb 23, 2017: Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress 39
Corporate Communications 40
Apr 24, 2017: Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance 40
Clinical Trials 41
Mar 19, 2018: Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair 41
Oct 26, 2017: Heron Therapeutics Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain and the Need for Opioid Analgesics for 72 Hours 43
Aug 09, 2017: Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA 44
Jan 04, 2017: Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty 46
Jan 04, 2017: Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies 47
Other Significant Developments 48
Jan 08, 2018: Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heron Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Heron Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Heron Therapeutics Raises USD200 Million in Public Offering of Shares 12
Heron Therapeutics Prices Public Offering of Shares for USD156 Million 14
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 16
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 17
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 19
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 21
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 23
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 24
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 26
Heron Therapeutics Inc, Key Competitors 27
Heron Therapeutics Inc, Key Employees 28
Heron Therapeutics Inc, Other Locations 29

List of Figures
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heron Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Heron Therapeutics Inc (HRTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Core-Mark Holding Company, Inc. (CORE):企業の財務・戦略的SWOT分析
    Core-Mark Holding Company, Inc. (CORE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Adamas Pharmaceuticals Inc (ADMS):企業の財務・戦略的SWOT分析
    Adamas Pharmaceuticals Inc (ADMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • JFE Holdings, Inc.:企業の戦略・SWOT・財務分析
    JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mesa Laboratories Inc (MLAB):企業の財務・戦略的SWOT分析
    Summary Mesa Laboratories Inc (Mesa) is a medical device company. It manufactures and markets validation and monitoring instruments. The company’s products include mesa biological indicators, DryCal gas flow calibrators, BGI ambient particulate sampling, DialyGuard dialysate meters, SureTorque cap t …
  • Mannatech Inc (MTEX):企業の財務・戦略的SWOT分析
    Mannatech Inc (MTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ContourGlobal plc (GLO):企業の財務・戦略的SWOT分析
    ContourGlobal plc (GLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Rubicon Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • Baxter International Inc (BAX):医療機器:M&Aディール及び事業提携情報
    Summary Baxter International Inc (Baxter) is a provider of healthcare products, including dialysis in acute and chronic conditions, sterile intravenous solutions, parenteral nutrition therapies, generic injectable pharmaceuticals, infusion systems and devices, inhaled anesthetics, and surgical hemos …
  • Cofidis Participations S.A.
    Cofidis Participations S.A. - Strategy, SWOT and Corporate Finance Report Summary Cofidis Participations S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Janssen Pharmaceutica NV:企業のM&A・事業提携・投資動向
    Janssen Pharmaceutica NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Janssen Pharmaceutica NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Kadmon Holdings Inc (KDMN):製薬・医療:M&Aディール及び事業提携情報
    Summary Kadmon Holdings Inc (Kadmon) is an integrated biopharmaceutical company that discovers, develops and markets small molecules and biologics for autoimmune and fibrotic diseases, various types of cancer, and genetic diseases. The company’s pipeline encompasses investigational candidates for th …
  • PSR Group BV:製薬・医療:M&Aディール及び事業提携情報
    Summary PSR Group BV (PSR) is a contract research and staffing consultancy service provider. The company operates through two divisions such as PSR Orphan Experts and PSR Pharma Resource. Its PSR Orphan Experts is a contract research organization that concentrates on orphan drug development. The com …
  • Trethera Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Trethera Corp (Trethera), formerly Triangle Therapeutics Inc is a clinical-stage biopharmaceutical company that discovers and develops novel therapies and treatment strategies in oncology. The corporation’s lead program combines TRE-515, a novel deoxycytidine kinase inhibitor with Triapine, …
  • GN Hearing AS-医療機器分野:企業M&A・提携分析
    Summary GN Hearing A/S (GN Hearing) formerly, GN ReSound A/S, a subsidiary of GN Store Nord A/S is a medical equipment company that provides advanced hearing health care solutions. It manufactures advanced technology hearing instruments and solutions for all types of ear-related problems. The compan …
  • Newpark Resources Inc (NR):企業の財務・戦略的SWOT分析
    Newpark Resources Inc (NR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Japan Post Holdings Co., Ltd.:企業の戦略・SWOT・財務情報
    Japan Post Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Japan Post Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Stada Arzneimittel AG (SAZ):医療機器:M&Aディール及び事業提携情報
    Summary Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of product …
  • Enea AB (ENEA):企業の財務・戦略的SWOT分析
    Summary Enea AB (Enea) is a technology company that provides software solutions. The company offers embedded technologies, testing and validation, certifications, software outsourcing, research and development centers, professional staffing and packaged services. It offers realtime operating system …
  • Elsalys Biotech SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Elsalys Biotech SA (Elsalys Biotech) is a pharmaceutical company that develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases. The company's pipeline programs include anti-CD160, for macular degeneration or certain retinopathie …
  • Veristat LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Veristat LLC (Veristat), a subsidiary of Veristat Holding Inc is a clinical research organization that conducts clinical trials. The organization offers services such as clinical project management, data management, clinical monitoring, biostatistics, medical writing, project management, reg …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆